Purple Biotech
REHOVOT, Center District · Biotechnology, Healthcare, Health Care
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240.
Key facts
- Headquarters
- REHOVOT, Center District
- Employees
- 13
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (PPBT)
- Website
- purple-biotech.com
- Company page
Recent activity at Purple Biotech
Purple Biotech funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2024 | Venture | $4.5M |
| Oct 2023 | Venture | $5.4M |
| May 2020 | Venture | $6.5M |
| Jan 2019 | Venture | $6.0M |
| Jun 2018 | Venture | $8.2M |
Leadership
- Isaac Israel, Executive Officer, Director
- Eric Rowinsky, Director
- Simcha Rock, Director
- Steven Steinberg, Director
- Ido Agmon, Director
- Ran Tzror, Director
- Revital Stern-Raff, Director
- Isaac Israel, Executive Officer, Director
- Eric Rowinsky, Director
- Simcha Rock, Director
- Steven Steinberg, Director
- Ido Agmon, Director
Verified email and direct lines for Purple Biotech’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Purple Biotech in the news
- Purple Biotech Ltd. Estimates – TASE:PPBT - TradingView (Oct 25, 2026)
- Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection - Yahoo Finance (Sep 02, 2026)
- H.C. Wainwright cuts Purple Biotech stock price target on preclinical progress - Investing.com (Aug 10, 2026)
- Why Is Purple Biotech Stock Gaining Wednesday? - Benzinga (Sep 02, 2026)
- Purple Biotech Ltd. Announces CEO Changes, Effective October 5, 2026 - marketscreener.com (Oct 05, 2026)
- Purple Biotech Reports Second Quarter 2026 Financial Results - GlobeNewswire (Aug 07, 2026)
- Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle - The Globe and Mail (Oct 06, 2026)
- Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) - Yahoo Finance (Jun 11, 2026)
Companies similar to Purple Biotech
- BioSig Technologies · Biotechnology, Healthcare, Health Care, Medical
- Galecto · Biotechnology, Healthcare, Health Care, Medical
- Amwell · Biotechnology, Healthcare, Health Care, Medical
- INVO Bioscience · Biotechnology, Healthcare, Health Care, Medical
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Medical
About Purple Biotech: questions and answers
What does Purple Biotech do?
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240.
Where is Purple Biotech headquartered?
Purple Biotech is headquartered in REHOVOT, Center District.
How many employees does Purple Biotech have?
Purple Biotech has about 13 employees.
Has Purple Biotech raised funding?
Yes. Fundz has recorded 5 funding events for Purple Biotech. The most recent, $4.5M, was in Jul 2024.
What is the latest news on Purple Biotech?
On May 12, 2025, Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Is Purple Biotech a public company?
Yes. Purple Biotech is publicly traded under the ticker PPBT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy